Barrett M S, Jones R N, Erwin M E
Department of Pathology, University of Iowa College of Medicine, Iowa City 52242.
J Clin Microbiol. 1993 Sep;31(9):2531-2. doi: 10.1128/jcm.31.9.2531-2532.1993.
Ceftizoxime was tested in triplicate against 100 clinical strains of Neisseria gonorrhoeae in accordance with National Committee for Clinical Laboratory Standards guidelines to establish susceptibility testing interpretive criteria. The MICs for 50 and 90% of the strains tested were 0.008 and 0.03 microgram/ml, respectively. These results confirm those of other studies reporting ceftizoxime's excellent activity against gonococci. Because no resistant strains were identified, a breakpoint MIC of < or = 0.5 microgram/ml was selected, with a correlate zone diameter of > or = 32 mm. Ceftizoxime appears to represent an alternative to other beta-lactamase-stable beta-lactams for cost-effective therapy of uncomplicated gonorrhea.
按照美国国家临床实验室标准委员会的指南，对100株淋病奈瑟菌临床菌株进行了头孢唑肟的三重测试，以确定药敏试验的解释标准。受试菌株中50%和90%的最低抑菌浓度（MIC）分别为0.008微克/毫升和0.03微克/毫升。这些结果证实了其他研究报告的头孢唑肟对淋球菌具有优异活性的结果。由于未鉴定出耐药菌株，因此选择了≤0.5微克/毫升的断点MIC，相关抑菌圈直径≥32毫米。对于单纯性淋病的经济有效治疗，头孢唑肟似乎是其他对β-内酰胺酶稳定的β-内酰胺类药物的替代选择。
